- $6.73bn
- $7.57bn
- $1.48bn
Biopharma firm Alkermes' Q3 revenue beats; raises 2025 outlook
Brief: Alkermes PLC Reports Third Quarter 2025 Financial Results
Brief: Alkermes Q3 Revenue USD 394.2 Million Vs. IBES Estimate USD 355.3 Million
U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic
Deals of the day-Mergers and acquisitions
Avadel rises after Alkermes' $2.1 billion buyout deal
Deals of the day-Mergers and acquisitions
Alkermes enters sleep medicine market with $2.1 billion Avadel deal (updated)
Avadel rises after Alkermes' $2.1 billion buyout deal
Alkermes to acquire Avadel for up to $2.1 billion
Alkermes sued over alleged scheme to block generic Vivitrol
Brief: Alkermes Says On Sept 9, Unit Granted Amneal Rights To Sell Generic Version Of Vivitrol - SEC Filing
Brief: Alkermes Appoints Joshua Reed As Chief Financial Officer
Brief: Alkermes Presents Detailed Positive Results From Vibrance-1 Phase 2 Study Of Alixorexton In Patients With Narcolepsy Type 1
Alkermes Plc reports results for the quarter ended June 30 - Earnings Summary
Drugmaker Alkermes beats Q2 revenue estimates, keeps FY ouitlook
U.S. STOCKS ON THE MOVE-Meta, Microsoft, Pinterest
U.S. STOCKS ON THE MOVE-Equinix, Gevo, Dentsply Sirona
U.S. STOCKS ON THE MOVE-Cummins, Biogen, Harmony Gold